Group 1 - The company plans to sell a total of 22.5 million shares, representing approximately 2.03% of the company's issued share capital after subscription [2] - The purchase price of HKD 32.55 per share reflects a discount of about 7.00% compared to the closing price of HKD 35.00 on August 20, 2025 [2] - The estimated net proceeds from the subscription are approximately HKD 722 million, which will be used for exploration and development projects related to the Jinling Mine and general working capital [2][3] Group 2 - The company has entered into an agreement with Victor Soar Investments Limited and Prominence Investment Holding Company Limited for the sale of shares [3] - The agreement includes provisions for the sale of 7.5 million shares at the same price of HKD 32.55 per share, which represents about 0.69% of the company's issued share capital as of the announcement date [3] - The placement agent will facilitate the purchase of shares by at least six subscribers on a best-efforts basis [3]

巨星传奇(06683)公布，配售事项及认购事项已分别于2025年7月30日及2025年8月5日完成。 配售事项的所有条件均已获达成，且配售事项已于2025年7月30日完成。合共3752.45万股配售股份(占 紧随认购事项完成后公司经扩大已发行股本约4.18%)已由配售代理按配售价每股配售股份9.13港元成功 配售予不少于六名承配人。 认购事项之所有条件已获达成，而认购事项已于2025年8月5日完成。合共3752.45万股认购股份(占紧随 认购事项完成后公司经扩大已发行股本约4.18%)已配发及发行予卖方。公司将从认购事项收取所得款项 净额约3.24亿港元。 ...

认购事项的所得款项净额估计约为4034万港元(已扣除相关费用及开支)。公司拟将认购事项全部所得款 项净额用于集团一般营运资金及一般业务。 智通财经APP讯，开拓药业-B(09939)发布公告，于2025年8月1日(交易时段前)，公司、童友之及卖方 (KT International Investment Limited)与配售代理订立该协议，据此，(i)卖方同意出售而配售代理同意(作 为卖方的代理)尽最大努力促使买方按每股股份2.08港元的价格购买卖方持有的合共2067.3万股股份，相 当于公司于本公告日期的已发行股本约4.62%;及(ii)卖方有条件同意作为委托人按认购价(相当于配售价 每股股份2.08港元)认购而公司有条件同意发行2067.3万股新股份(即认购股份)。 配售代理有条件同意作为卖方的代理尽最大努力配售2067.3万股股份，相当于经认购事项扩大后的公司 已发行股本约4.42%(假设除发行认购股份外，公司已发行股本自本公告日期起至认购事项完成止并无变 动)。配售价/认购价2.08港元较：股份于2025年7月31日在联交所所报的收市价每股2.56港元折让约 18.75%。 ...

Core Viewpoint - The company, Ascentage Pharma-B (06855), has entered into a placement and subscription agreement to issue up to 22 million shares at a price of HKD 68.60 per share, which represents a discount to the market price, aiming to raise approximately HKD 15.09 billion for further commercialization and development of its core products [1][2][3] Group 1: Placement and Subscription Details - The placement price of HKD 68.60 per share is approximately 8.17% lower than the closing price of HKD 74.70 on the date of the agreement [2] - The maximum number of shares to be sold represents about 6.29% of the company's existing issued share capital as of the announcement date [1] - The expected net proceeds from the subscription are estimated to be around HKD 14.93 billion, with a net price per share of approximately HKD 67.84 [2] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated for commercialization efforts, including expanding coverage and improving patient access [3] - About 35% will be used for global clinical development to advance the company's core pipeline products [3] - The remaining 25% will be directed towards infrastructure and operational funding to strengthen global operations [3]